Frequency and Phenotype of Aquaporin-4-IgG and Coexistent Autoimmune Encephalitis Antibody Biomarkers

ObjectiveAims of this study were 1) to evaluate which autoimmune encephalitis autoantibodies can co-exist in patients with aquaporin-4-IgG (AQP4-IgG) and 2) what is the clinical phenotype of patients with AQP4-IgG+ and autoimmune encephalitis autoantibodies. BackgroundNeuromyelitis optica spectrum disorder (NMOSD) typically presents with optic neuritis, myelitis, or brainstem attacks. Rarely, patients can experience encephalopathy. NMOSD patients often have co-existent systemic autoimmunity. Design/MethodsTo ensure homogeneity in tests, the frequency of AQP4-IgG and autoimmune encephalitis antibodies association was evaluated on patients with AQP4-IgG+ tested for autoimmune encephalitis antibodies (2018- 2022). Then, we interrogated the Neuroimmunology laboratory database for AQP4-IgG+ patients (2007 to 2022, n=6,645) and identified patients with coexistent NMDA-R-IgG or GFAP-IgG. Clinical and radiological features of these patients were then compared to those of a control group of AQP4-IgG+ NMOSD from the clinical database. ResultsCoexistent neuronal/glial-IgGs were found in 1/128 (0.7%) sera and 21/126 (17%) cerebrospinal fluid tested. NMDA-R-IgG was the most frequent antibody detected in children (6/8 [80%], GFAP-IgG was the most common in adults (9/13 [69%]). We identified 21 AQP4-IgG+ with coexistent neuronal or glial antibodies and clinico-radiological data (9 isolated NMDA-R-IgG, 9 NMDA-R-IgG/GFAP-IgG, 2 isolated GFAP-IgG, and 1 NMDA-R-IgG/MOG-IgG). Compared to 311 AQP4-IgG+NMOSD in the clinical database, those with coexistent neuronal/glial antibodies had a higher frequency of encephalopathy, ovarian tumors, temporal lobe, basal ganglia and diencephalic involvement (all p<0.001). ConclusionsAQP4-IgG can rarely coexist with autoimmune encephalitis autoantibodies, especially with NMDA-R-IgG and GFAP-IgG. These patients usually have features of autoimmune encephalitis, and several had ovarian teratoma.

Authors

Publication Details

Journal
Neurology
Published
2024-10-08
DOI
https://doi.org/10.1212/01.wnl.0001051696.89300.fd
Primary Topic
Autoimmune Neurological Disorders and Treatments
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Frequency and Phenotype of Aquaporin-4-IgG and Coexistent Autoimmune Encephalitis Antibody Biomarkers

Amy Kunchok, Thomas Shoemaker, Jacqueline Nicholas, Αναστασία Ζεκερίδου et al.
Neurology
Autoimmune Neurological Disorders and Treatments
article

Frequency and Phenotype of Aquaporin-4-IgG and Coexistent Autoimmune Encephalitis Antibody Biomarkers

Amy Kunchok, Thomas Shoemaker, Jacqueline Nicholas, Αναστασία Ζεκερίδου, Laura Cacciaguerra, Eoin P. Flanagan, Emmanuelle L. Waubant, Wendy G. Mitchell, Kurt Sieloff, Vanessa Sui, Andrew B. McKeon, Karen S. Fernández, William Meador, Nusrat Ahsan, Shruti Agnihotri, Binxia Yang, Amy May Lin Quek, Erin McLeod, Sean J Pittock
article en

Abstract

ObjectiveAims of this study were 1) to evaluate which autoimmune encephalitis autoantibodies can co-exist in patients with aquaporin-4-IgG (AQP4-IgG) and 2) what is the clinical phenotype of patients with AQP4-IgG+ and autoimmune encephalitis autoantibodies. BackgroundNeuromyelitis optica spectrum disorder (NMOSD) typically presents with optic neuritis, myelitis, or brainstem attacks. Rarely, patients can experience encephalopathy. NMOSD patients often have co-existent systemic autoimmunity. Design/MethodsTo ensure homogeneity in tests, the frequency of AQP4-IgG and autoimmune encephalitis antibodies association was evaluated on patients with AQP4-IgG+ tested for autoimmune encephalitis antibodies (2018- 2022). Then, we interrogated the Neuroimmunology laboratory database for AQP4-IgG+ patients (2007 to 2022, n=6,645) and identified patients with coexistent NMDA-R-IgG or GFAP-IgG. Clinical and radiological features of these patients were then compared to those of a control group of AQP4-IgG+ NMOSD from the clinical database. ResultsCoexistent neuronal/glial-IgGs were found in 1/128 (0.7%) sera and 21/126 (17%) cerebrospinal fluid tested. NMDA-R-IgG was the most frequent antibody detected in children (6/8 [80%], GFAP-IgG was the most common in adults (9/13 [69%]). We identified 21 AQP4-IgG+ with coexistent neuronal or glial antibodies and clinico-radiological data (9 isolated NMDA-R-IgG, 9 NMDA-R-IgG/GFAP-IgG, 2 isolated GFAP-IgG, and 1 NMDA-R-IgG/MOG-IgG). Compared to 311 AQP4-IgG+NMOSD in the clinical database, those with coexistent neuronal/glial antibodies had a higher frequency of encephalopathy, ovarian tumors, temporal lobe, basal ganglia and diencephalic involvement (all p<0.001). ConclusionsAQP4-IgG can rarely coexist with autoimmune encephalitis autoantibodies, especially with NMDA-R-IgG and GFAP-IgG. These patients usually have features of autoimmune encephalitis, and several had ovarian teratoma.

NeurologyVol. 103(7_Supplement_1)
U.S. Department of Defense
Zero hunger
Openalex Percentile: Top 73%
Autoimmune Neurological Disorders and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.